董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Maslowski | 男 | President and Chief Executive Officer and Director | 42 | 63.90万美元 | 未持股 | 2017-04-27 |
| Douglas J. Swirsky | 男 | Chairman of the Board | 47 | 8.73万美元 | 未持股 | 2017-04-27 |
| David Pernock | 男 | Chairman of the Board and Chief Executive Officer | 69 | 125.96万美元 | 未持股 | 2017-04-27 |
| Kelvin Moore | 男 | Director | 68 | 10.92万美元 | 未持股 | 2017-04-27 |
| Marc B. Mazur | 男 | Director | 58 | 8.82万美元 | 未持股 | 2017-04-27 |
| Marcus Smith | 男 | Director | 62 | 6.92万美元 | 未持股 | 2017-04-27 |
| Julian P. Kirk | 男 | Director | 43 | 6.92万美元 | 未持股 | 2017-04-27 |
| Christine St.Clare | 女 | Director | 66 | 8.62万美元 | 未持股 | 2017-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Maslowski | 男 | President and Chief Executive Officer and Director | 42 | 63.90万美元 | 未持股 | 2017-04-27 |
| Keith A. Goldan | 男 | Senior Vice President, Chief Financial Officer and Treasurer | 53 | 71.37万美元 | 未持股 | 2017-04-27 |
| Michael F. Marino | 男 | Senior Vice President, General Counsel and Corporate Secretary | 48 | 60.10万美元 | 未持股 | 2017-04-27 |
| David Pernock | 男 | Chairman of the Board and Chief Executive Officer | 69 | 125.96万美元 | 未持股 | 2017-04-27 |
董事简历
中英对照 | 中文 | 英文- John Maslowski
-
John Maslowski，他于2005年3月加入我们，曾一直担任我们的负责科学事务的副总裁（2012年6月以来）。加入我们之前，他曾担任Wyeth Pharmaceuticals公司（现称为Pfizer公司）的多种职务（从2001年8月到2005年2月），最终担任制造质量保证经理。加入Wyeth公司之前，他曾担任Merck & Co。、Teva Pharmaceutical Industries公司的多种职务。他持有the Ursinus College的生物学学士学位，以及生物学学士学位的生物学硕士学位。
John Maslowski has served as a member of our Board since December 2016. Mr. Maslowski is Fibrocell’s Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. now Pfizer, Inc., eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University. - John Maslowski，他于2005年3月加入我们，曾一直担任我们的负责科学事务的副总裁（2012年6月以来）。加入我们之前，他曾担任Wyeth Pharmaceuticals公司（现称为Pfizer公司）的多种职务（从2001年8月到2005年2月），最终担任制造质量保证经理。加入Wyeth公司之前，他曾担任Merck & Co。、Teva Pharmaceutical Industries公司的多种职务。他持有the Ursinus College的生物学学士学位，以及生物学学士学位的生物学硕士学位。
- John Maslowski has served as a member of our Board since December 2016. Mr. Maslowski is Fibrocell’s Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. now Pfizer, Inc., eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.
- Douglas J. Swirsky
-
Douglas J. Swirsky， 他曾担任总裁兼首席执行官和董事（自2013年9月以来）。他于2006年加入GenVec ，并担任首席财务官、司库和公司秘书。加入GenVec公司之前， 他担任Stifel Nicolaus公司生命科学投资银行业务主管和总经理（从2005年到2006年），并担任 Legg Mason公司银行投资员（从2002年到2005年Stifel Financial 收购Legg Mason的资本市场业务）。他是注册会计师和CFA特许持有人，也曾任职瑞士联合银行、普惠公司和摩根士丹利投资银行职员。他的经验还涉及公共会计和咨询。他获得了波士顿大学工商管理学士学位，以及西北大学凯洛格管理学院的工商管理硕士学位。他是Fibrocell Science公司的董事。在过去的五年中，他也曾任职PolyMedix公司的董事会。
Douglas J. Swirsky was appointed as a director of Cellectar in April 2017 and Chairman of our Board in August 2017. Since February 2021 Mr. Swirsky has served as Chief Financial Officer and Treasurer of AavantiBio. Prior to AavantiBio, Mr. Swirsky served as President, Chief Executive Officer and a director of Rexahn Pharmaceuticals from November 2018 to November 2020; having previously served as Rexahn’s President and Chief Financial Officer from January 2018 until his appointment as CEO. Prior to Rexahn, Mr. Swirsky served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage biopharmaceutical company, from 2014 to June 2017. From 2006 through 2014 Mr. Swirsky served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder. Mr. Swirsky currently serves on the board of directors of NeuroBo Pharmaceuticals, Inc. Within the past five years, Mr. Swirsky has also served on the board of Fibrocell Science, Inc., Pernix Therapeutics Holdings, Inc. and GenVec, Inc.. Mr. Swirsky is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. - Douglas J. Swirsky， 他曾担任总裁兼首席执行官和董事（自2013年9月以来）。他于2006年加入GenVec ，并担任首席财务官、司库和公司秘书。加入GenVec公司之前， 他担任Stifel Nicolaus公司生命科学投资银行业务主管和总经理（从2005年到2006年），并担任 Legg Mason公司银行投资员（从2002年到2005年Stifel Financial 收购Legg Mason的资本市场业务）。他是注册会计师和CFA特许持有人，也曾任职瑞士联合银行、普惠公司和摩根士丹利投资银行职员。他的经验还涉及公共会计和咨询。他获得了波士顿大学工商管理学士学位，以及西北大学凯洛格管理学院的工商管理硕士学位。他是Fibrocell Science公司的董事。在过去的五年中，他也曾任职PolyMedix公司的董事会。
- Douglas J. Swirsky was appointed as a director of Cellectar in April 2017 and Chairman of our Board in August 2017. Since February 2021 Mr. Swirsky has served as Chief Financial Officer and Treasurer of AavantiBio. Prior to AavantiBio, Mr. Swirsky served as President, Chief Executive Officer and a director of Rexahn Pharmaceuticals from November 2018 to November 2020; having previously served as Rexahn’s President and Chief Financial Officer from January 2018 until his appointment as CEO. Prior to Rexahn, Mr. Swirsky served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage biopharmaceutical company, from 2014 to June 2017. From 2006 through 2014 Mr. Swirsky served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder. Mr. Swirsky currently serves on the board of directors of NeuroBo Pharmaceuticals, Inc. Within the past five years, Mr. Swirsky has also served on the board of Fibrocell Science, Inc., Pernix Therapeutics Holdings, Inc. and GenVec, Inc.. Mr. Swirsky is a member of the Compensation Committee and the Nominating and Corporate Governance Committee.
- David Pernock
-
David Pernock自2009年9月担任董事会主席，同时自2010年2月担任首席执行官。从1993年12月到2009年11月，Pernock先生在葛兰素史克公司担任各种职务，最终担任制药、疫苗生物制剂、肿瘤、急性病护理以及艾滋病毒部门的高级副总裁。从2009年5月到2011年2月，Pernock先生担任Martek生物科学公司的董事。Pernock先生从亚利桑那州立大学获得企业管理学士学位。Pernock先生在董事会和管理委员会之间进行沟通，并监管管理委员会以实现董事会到的战略目标。
David Pernock has served as our President and Chief Commercial Officer since January 2017. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017 Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009 Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines biologics, oncology, acute care, and HIV divisions. From May 2009 until February 2011 Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University. - David Pernock自2009年9月担任董事会主席，同时自2010年2月担任首席执行官。从1993年12月到2009年11月，Pernock先生在葛兰素史克公司担任各种职务，最终担任制药、疫苗生物制剂、肿瘤、急性病护理以及艾滋病毒部门的高级副总裁。从2009年5月到2011年2月，Pernock先生担任Martek生物科学公司的董事。Pernock先生从亚利桑那州立大学获得企业管理学士学位。Pernock先生在董事会和管理委员会之间进行沟通，并监管管理委员会以实现董事会到的战略目标。
- David Pernock has served as our President and Chief Commercial Officer since January 2017. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017 Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009 Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines biologics, oncology, acute care, and HIV divisions. From May 2009 until February 2011 Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University.
- Kelvin Moore
-
Kelvin Moore自2009年9月担任Fibrocell公司的他在银行业的30多年中有担任各种职务的经验。从2009年3月到2010年晚些时候，Moore先生担任总部位于英国的海上运输集团，并担任咨询销售董事，主要负责开发从海运集装箱改造成住房建筑。从2008年7月到2010年9月，Moore先生担任橡树文化开发公司的董事，该公司正在开发社交网络平台。在2004年6月到2008年5月间，Moore先生是出口策略规划公司的高级咨询师，主要负责公司的出售。目前，他运营自己的咨询公司，主要向中小企业主提供专业知识和指导。Moore先生从伦敦大学获得地理学和纯数学学位。
Kelvin Moore has served as a member of our Board since September 2009. He has over 40 years of experience in a wide range of roles within the banking industry. From March 2009 to late 2010 Mr. Moore served as the consultant sales director for the UK-based Seaborne Group, developing its business in building constructions from converting shipping sea containers. From July 2008 to September 2010 Mr. Moore was a director of Acorn Cultural Developments Limited which developed a social networking site. Between June 2004 and May 2008 Mr. Moore was a senior advisor with Exit Strategy Planning, dealing with the sale of businesses. Currently, he runs his own consulting business providing expertise and mentoring to owners of small and medium-sized enterprises. Mr. Moore holds a London University Degree in Geography and Pure Mathematics. - Kelvin Moore自2009年9月担任Fibrocell公司的他在银行业的30多年中有担任各种职务的经验。从2009年3月到2010年晚些时候，Moore先生担任总部位于英国的海上运输集团，并担任咨询销售董事，主要负责开发从海运集装箱改造成住房建筑。从2008年7月到2010年9月，Moore先生担任橡树文化开发公司的董事，该公司正在开发社交网络平台。在2004年6月到2008年5月间，Moore先生是出口策略规划公司的高级咨询师，主要负责公司的出售。目前，他运营自己的咨询公司，主要向中小企业主提供专业知识和指导。Moore先生从伦敦大学获得地理学和纯数学学位。
- Kelvin Moore has served as a member of our Board since September 2009. He has over 40 years of experience in a wide range of roles within the banking industry. From March 2009 to late 2010 Mr. Moore served as the consultant sales director for the UK-based Seaborne Group, developing its business in building constructions from converting shipping sea containers. From July 2008 to September 2010 Mr. Moore was a director of Acorn Cultural Developments Limited which developed a social networking site. Between June 2004 and May 2008 Mr. Moore was a senior advisor with Exit Strategy Planning, dealing with the sale of businesses. Currently, he runs his own consulting business providing expertise and mentoring to owners of small and medium-sized enterprises. Mr. Moore holds a London University Degree in Geography and Pure Mathematics.
- Marc B. Mazur
-
Marc B. Mazur自2010年4月担任Fibrocell公司董事。Mazur先生目前担任Brightwood资本咨询师基金会的咨询实施，该基金会是一个注册资金10亿美元的基金会，他还是Brevan Howard股份有限公司董事会主席，该公司是一家国际宏观对冲基金公司从2006年10月直到2009年12月，Mazur先生担任Brevan Howard美国资产管理公司首席执行官，该公司是总部位于伦敦的Brevan Howard公司在美国的分支机构。在2001年，Mazur先生创立了大师资本集团，该公司是一家私有投资和咨询公司，主要对健康护理、金融服务以及不动产领域的公司提供资本、公司发展以及策略规划建议。Mazur先生在1981年从哥伦比亚大学获得政治科学学士学位，在1984年从维拉诺瓦大学获得法学博士学位。
Marc B. Mazur has served as a member of our Board since April 2010. Mr. Mazur currently serves as an advisor to Brightwood Capital Advisors, an investment fund. From October 2006 until December 2009 Mr. Mazur served as the Chief Executive Officer of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard. Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. He has served on a number of private company boards in the wellness, population health and medical device fields. Mr. Mazur received his B.A. in political science from Columbia University and a J.D. from Villanova University School of Law. - Marc B. Mazur自2010年4月担任Fibrocell公司董事。Mazur先生目前担任Brightwood资本咨询师基金会的咨询实施，该基金会是一个注册资金10亿美元的基金会，他还是Brevan Howard股份有限公司董事会主席，该公司是一家国际宏观对冲基金公司从2006年10月直到2009年12月，Mazur先生担任Brevan Howard美国资产管理公司首席执行官，该公司是总部位于伦敦的Brevan Howard公司在美国的分支机构。在2001年，Mazur先生创立了大师资本集团，该公司是一家私有投资和咨询公司，主要对健康护理、金融服务以及不动产领域的公司提供资本、公司发展以及策略规划建议。Mazur先生在1981年从哥伦比亚大学获得政治科学学士学位，在1984年从维拉诺瓦大学获得法学博士学位。
- Marc B. Mazur has served as a member of our Board since April 2010. Mr. Mazur currently serves as an advisor to Brightwood Capital Advisors, an investment fund. From October 2006 until December 2009 Mr. Mazur served as the Chief Executive Officer of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard. Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. He has served on a number of private company boards in the wellness, population health and medical device fields. Mr. Mazur received his B.A. in political science from Columbia University and a J.D. from Villanova University School of Law.
- Marcus Smith
-
Marcus Smith自2012年10月担任公司董事。Smith先生自第三证券公司创立之初便加入公司，并且一直主要负责法律事务和交易执行。从1996年8月到2004年4月，Smith先生担任新河制药集团高级副总裁、法律总顾问、秘书长以及董事会成员。Smith先生从佐治亚大学获得工商管理学学士学位。
Marcus Smith has served as a member of our Board since October 2012. Mr. Smith joined Third Security, LLC upon its inception and has since been principally responsible for legal matters and transaction execution. From August 1996 to April 2004 Mr. Smith served as Senior Vice President, General Counsel, Secretary and member of the board of directors of New River Pharmaceuticals Inc. Mr. Smith received his B.B.A. and his J.D. from the University of Georgia. - Marcus Smith自2012年10月担任公司董事。Smith先生自第三证券公司创立之初便加入公司，并且一直主要负责法律事务和交易执行。从1996年8月到2004年4月，Smith先生担任新河制药集团高级副总裁、法律总顾问、秘书长以及董事会成员。Smith先生从佐治亚大学获得工商管理学学士学位。
- Marcus Smith has served as a member of our Board since October 2012. Mr. Smith joined Third Security, LLC upon its inception and has since been principally responsible for legal matters and transaction execution. From August 1996 to April 2004 Mr. Smith served as Senior Vice President, General Counsel, Secretary and member of the board of directors of New River Pharmaceuticals Inc. Mr. Smith received his B.B.A. and his J.D. from the University of Georgia.
- Julian P. Kirk
-
Julian P. Kirk自2012年10月担任公司董事。Kirk先生是第三证券公司常务董事，他从公司成立便任职于此以及其投资组合公司的投资管理基金。他还监管第三证券公司内部运营。Kirk先生自2013年6月担任AmpliPhi生物科学公司（处方药编号：APHB）董事会成员。自2010年8月，他任职于新河谷经济开发联盟董事会。从2006年10月到2011年12月，他担任IntelliMat股份有限公司董事会成员，同时从2008年9月年到2011年12月担任董事会联合主席。从2005年9月到2011年12月，Kirk先生在丰收制药公司担任总裁。Kirk先生还从2008年6月到2010年3月担任ECDS公司受托人委员会主席。Kirk先生从弗吉尼亚大学作为维州大学的艾克斯学者毕业毕业。
Julian P. Kirk has served as a member of our Board since October 2012. Mr. Kirk is a Managing Director of Third Security, LLC, where he has worked since the firm’s inception with several portfolio companies of its managed investment funds. He is also involved with the oversight of Third Security, LLC’s internal operations. Mr. Kirk was a member of the board of directors of AmpliPhi Biosciences Corporation NYSE: APHB from June 2013 to April 2015. Since August 2010 he has served on the board of the New River Valley Economic Development Alliance. From October 2006 until December 2011 he served as a member of the board of directors of IntelliMat, Inc. and as Co-Chairman of its board of directors between September 2008 and December 2011. From September 2005 until December 2011 Mr. Kirk served as President of Harvest Pharmaceuticals Inc. Mr. Kirk also served as Chairman of the board of managers of ECDS, LLC from June 2008 until March 2010. Mr. Kirk graduated as an Echols Scholar from the University of Virginia. - Julian P. Kirk自2012年10月担任公司董事。Kirk先生是第三证券公司常务董事，他从公司成立便任职于此以及其投资组合公司的投资管理基金。他还监管第三证券公司内部运营。Kirk先生自2013年6月担任AmpliPhi生物科学公司（处方药编号：APHB）董事会成员。自2010年8月，他任职于新河谷经济开发联盟董事会。从2006年10月到2011年12月，他担任IntelliMat股份有限公司董事会成员，同时从2008年9月年到2011年12月担任董事会联合主席。从2005年9月到2011年12月，Kirk先生在丰收制药公司担任总裁。Kirk先生还从2008年6月到2010年3月担任ECDS公司受托人委员会主席。Kirk先生从弗吉尼亚大学作为维州大学的艾克斯学者毕业毕业。
- Julian P. Kirk has served as a member of our Board since October 2012. Mr. Kirk is a Managing Director of Third Security, LLC, where he has worked since the firm’s inception with several portfolio companies of its managed investment funds. He is also involved with the oversight of Third Security, LLC’s internal operations. Mr. Kirk was a member of the board of directors of AmpliPhi Biosciences Corporation NYSE: APHB from June 2013 to April 2015. Since August 2010 he has served on the board of the New River Valley Economic Development Alliance. From October 2006 until December 2011 he served as a member of the board of directors of IntelliMat, Inc. and as Co-Chairman of its board of directors between September 2008 and December 2011. From September 2005 until December 2011 Mr. Kirk served as President of Harvest Pharmaceuticals Inc. Mr. Kirk also served as Chairman of the board of managers of ECDS, LLC from June 2008 until March 2010. Mr. Kirk graduated as an Echols Scholar from the University of Virginia.
- Christine St.Clare
-
Christine St.Clare自2013年2月担任公司董事。St.Clare女士最近完成了在毕马威会计事务所35年的职业生涯，在该事务所她担任了4年任期的董事会成员，同时担任审计和金融委员会主席。作为一名审计合伙人，她在一些毕马威会计事务所的大型客户担任参与合伙人。接下来，她担任公司咨询业务的咨询合伙人，并关注于内部审计、风险和合规业务。与此同时她是东南顾客市场业务合伙人的负责人。她目前任职于聚合物集团董事会，同时担任审计委员会主席。她还任职于以下公司或机构咨询委员会，包括华利安诺基公司（一家关注于投资银行咨询业务的中型国际企业）；妇女集团董事；以及艾莫利大学古兹维塔商学院 。
Christine St.Clare,joined the Board of AquaBounty in May 2014. She is a former Audit Partner at KPMG LLP ("KPMG") serving publicly traded companies until 2005, after which she transferred to the Advisory Practice, working in the Internal Audit, Risk and Compliance Practice until her retirement in 2010. She also served a four-year term on KPMG's Board of Directors, where she chaired KPMG's Audit and Finance Committee for three of the four years. She has served on the Board of Directors for Tilray, Inc. ("Tilray") (NASDAQ:TLRY), from their 2018 IPO through April 2021. At Tilray, she chaired the Audit Committee and was a member of the Nominating & Governance Committee and the Compensation Committee. She formerly served on the boards of both Fibrocell Science, Inc. ("Fibrocell"), a company that specialized in the development of personalized biologics and Polymer Group, Inc. ("Polymer"), a global manufacturer of engineered materials. Fibrocell was a NASDAQ listed company and Polymer was a Blackstone portfolio company with publicly traded debt. For both Fibrocell and Polymer, Ms. St.Clare served as the Audit Committee Chair until their respective sales to strategic buyers. Ms. St.Clare holds a Bachelor of Science in accounting from California State University at Long Beach and has been a licensed Certified Public Accountant in California, Texas and Georgia. - Christine St.Clare自2013年2月担任公司董事。St.Clare女士最近完成了在毕马威会计事务所35年的职业生涯，在该事务所她担任了4年任期的董事会成员，同时担任审计和金融委员会主席。作为一名审计合伙人，她在一些毕马威会计事务所的大型客户担任参与合伙人。接下来，她担任公司咨询业务的咨询合伙人，并关注于内部审计、风险和合规业务。与此同时她是东南顾客市场业务合伙人的负责人。她目前任职于聚合物集团董事会，同时担任审计委员会主席。她还任职于以下公司或机构咨询委员会，包括华利安诺基公司（一家关注于投资银行咨询业务的中型国际企业）；妇女集团董事；以及艾莫利大学古兹维塔商学院 。
- Christine St.Clare,joined the Board of AquaBounty in May 2014. She is a former Audit Partner at KPMG LLP ("KPMG") serving publicly traded companies until 2005, after which she transferred to the Advisory Practice, working in the Internal Audit, Risk and Compliance Practice until her retirement in 2010. She also served a four-year term on KPMG's Board of Directors, where she chaired KPMG's Audit and Finance Committee for three of the four years. She has served on the Board of Directors for Tilray, Inc. ("Tilray") (NASDAQ:TLRY), from their 2018 IPO through April 2021. At Tilray, she chaired the Audit Committee and was a member of the Nominating & Governance Committee and the Compensation Committee. She formerly served on the boards of both Fibrocell Science, Inc. ("Fibrocell"), a company that specialized in the development of personalized biologics and Polymer Group, Inc. ("Polymer"), a global manufacturer of engineered materials. Fibrocell was a NASDAQ listed company and Polymer was a Blackstone portfolio company with publicly traded debt. For both Fibrocell and Polymer, Ms. St.Clare served as the Audit Committee Chair until their respective sales to strategic buyers. Ms. St.Clare holds a Bachelor of Science in accounting from California State University at Long Beach and has been a licensed Certified Public Accountant in California, Texas and Georgia.
高管简历
中英对照 | 中文 | 英文- John Maslowski
John Maslowski，他于2005年3月加入我们，曾一直担任我们的负责科学事务的副总裁（2012年6月以来）。加入我们之前，他曾担任Wyeth Pharmaceuticals公司（现称为Pfizer公司）的多种职务（从2001年8月到2005年2月），最终担任制造质量保证经理。加入Wyeth公司之前，他曾担任Merck & Co。、Teva Pharmaceutical Industries公司的多种职务。他持有the Ursinus College的生物学学士学位，以及生物学学士学位的生物学硕士学位。
John Maslowski has served as a member of our Board since December 2016. Mr. Maslowski is Fibrocell’s Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. now Pfizer, Inc., eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.- John Maslowski，他于2005年3月加入我们，曾一直担任我们的负责科学事务的副总裁（2012年6月以来）。加入我们之前，他曾担任Wyeth Pharmaceuticals公司（现称为Pfizer公司）的多种职务（从2001年8月到2005年2月），最终担任制造质量保证经理。加入Wyeth公司之前，他曾担任Merck & Co。、Teva Pharmaceutical Industries公司的多种职务。他持有the Ursinus College的生物学学士学位，以及生物学学士学位的生物学硕士学位。
- John Maslowski has served as a member of our Board since December 2016. Mr. Maslowski is Fibrocell’s Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. now Pfizer, Inc., eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.
- Keith A. Goldan
Keith A. Goldan.，Goldan先生在2015年3月加入我们，担任我们的高级副总裁，首席财务官，财务主管和公司秘书。在加入我们之前，从2008年11月到2014年3月，Goldan先生担任NuPathe Inc.高级副总裁兼首席财务官，该公司是一家专业制药公司，在2014年被Teva Pharmaceutical Industries Ltd.收购。从2014年3月至2015年3月，Goldan先生在执行战略制药行业担任财务和运营咨询服务。在加入NuPathe Inc 。之前，从2004年10月到2008年10月， Goldan先生担任PuriCore plc的首席财务官和董事会成员，该公司是一家医疗技术公司，在伦敦证券交易所上市。Goldan先生在此之前，担任Biosyn, Inc.副总裁兼首席财务官，该公司是一家专业制药公司，在ViroPharma Incorporated, Century Capital Associates担任各种职位，后者是一家专业咨询公司，还在the Healthcare & Life Sciences Practice of KPMG, LLP。任职。Goldan先生获得the Robert H. Smith School of Business at the University of Maryland金融学学士学位和The Wharton School at the University of Pennsylvania的MBA学位。
Keith A. Goldan has served as our Chief Financial Officer since January 2017. From March 2015 to January 2017 Mr. Goldan served as Senior Vice President, Chief Financial Officer and Treasurer of Fibrocell Science, Inc., a publicly-held gene therapy company, and also served as its Corporate Secretary from March 2015 to June 2015. From March 2014 to March 2015 Mr. Goldan served as a financial and operational consultant to companies in the pharmaceutical industry. From November 2008 to March 2014 Mr. Goldan served as Senior Vice President and Chief Financial Officer of NuPathe Inc., a specialty pharmaceutical company that was acquired by Teva Pharmaceutical Industries Ltd. Mr. Goldan previously served as Chief Financial Officer and a member of the board of directors of PuriCore plc, a medical technology company listed on the London Stock Exchange. Earlier in his career, Mr. Goldan served as Vice President and Chief Financial Officer of Biosyn, Inc., a specialty pharmaceutical company, and in a variety of roles with ViroPharma and the Healthcare & Life Sciences Practice of KPMG. Mr. Goldan earned a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from The Wharton School at the University of Pennsylvania.- Keith A. Goldan.，Goldan先生在2015年3月加入我们，担任我们的高级副总裁，首席财务官，财务主管和公司秘书。在加入我们之前，从2008年11月到2014年3月，Goldan先生担任NuPathe Inc.高级副总裁兼首席财务官，该公司是一家专业制药公司，在2014年被Teva Pharmaceutical Industries Ltd.收购。从2014年3月至2015年3月，Goldan先生在执行战略制药行业担任财务和运营咨询服务。在加入NuPathe Inc 。之前，从2004年10月到2008年10月， Goldan先生担任PuriCore plc的首席财务官和董事会成员，该公司是一家医疗技术公司，在伦敦证券交易所上市。Goldan先生在此之前，担任Biosyn, Inc.副总裁兼首席财务官，该公司是一家专业制药公司，在ViroPharma Incorporated, Century Capital Associates担任各种职位，后者是一家专业咨询公司，还在the Healthcare & Life Sciences Practice of KPMG, LLP。任职。Goldan先生获得the Robert H. Smith School of Business at the University of Maryland金融学学士学位和The Wharton School at the University of Pennsylvania的MBA学位。
- Keith A. Goldan has served as our Chief Financial Officer since January 2017. From March 2015 to January 2017 Mr. Goldan served as Senior Vice President, Chief Financial Officer and Treasurer of Fibrocell Science, Inc., a publicly-held gene therapy company, and also served as its Corporate Secretary from March 2015 to June 2015. From March 2014 to March 2015 Mr. Goldan served as a financial and operational consultant to companies in the pharmaceutical industry. From November 2008 to March 2014 Mr. Goldan served as Senior Vice President and Chief Financial Officer of NuPathe Inc., a specialty pharmaceutical company that was acquired by Teva Pharmaceutical Industries Ltd. Mr. Goldan previously served as Chief Financial Officer and a member of the board of directors of PuriCore plc, a medical technology company listed on the London Stock Exchange. Earlier in his career, Mr. Goldan served as Vice President and Chief Financial Officer of Biosyn, Inc., a specialty pharmaceutical company, and in a variety of roles with ViroPharma and the Healthcare & Life Sciences Practice of KPMG. Mr. Goldan earned a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from The Wharton School at the University of Pennsylvania.
- Michael F. Marino
Michael F. Marino， Marino先生，2010年10月以来一直是Optinose, Inc.的副总裁，总顾问和秘书。加入NuPathe之前，从2005年3月至2010年10月，Marino先生在Morgan, Lewis & Bockius LLP任职，从2001年10月至2005年3月，在WilmerHale LLP律师事务所任职。在Morgan, Lewis & Bockius 和 WilmerHale时，Marino先生的实践主要集中在为生命科学技术和其他公司提供广泛问题建议，包括并购、证券、金融、公司治理、遵从性和其他一般公司事务。Marino先生拥有Villanova University会计学士学位和波士顿大学法学院法学博士学位。
Michael F. Marino,has served as Optinose, Inc. Chief Legal Officer and Corporate Secretary since January 2017 and as a member of the board of directors of OptiNose AS since June 2018. Prior to joining Optinose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell Science, Inc., a publicly-traded cell and gene therapy company, from 2015 to 2017, and as Senior Vice President, General Counsel and Corporate Secretary of NuPathe Inc., a publicly-traded specialty pharmaceutical company from 2010 until the sale of NuPathe to Teva Pharmaceutical Industries Ltd. in 2014. From 2001 to 2010, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP and WilmerHale LLP where his practice focused on mergers and acquisitions, financing transactions, collaborations, corporate governance, securities and other general corporate matters. Mr. Marino earned a B.S. in Accountancy from Villanova University and a J.D. from Boston College Law School.- Michael F. Marino， Marino先生，2010年10月以来一直是Optinose, Inc.的副总裁，总顾问和秘书。加入NuPathe之前，从2005年3月至2010年10月，Marino先生在Morgan, Lewis & Bockius LLP任职，从2001年10月至2005年3月，在WilmerHale LLP律师事务所任职。在Morgan, Lewis & Bockius 和 WilmerHale时，Marino先生的实践主要集中在为生命科学技术和其他公司提供广泛问题建议，包括并购、证券、金融、公司治理、遵从性和其他一般公司事务。Marino先生拥有Villanova University会计学士学位和波士顿大学法学院法学博士学位。
- Michael F. Marino,has served as Optinose, Inc. Chief Legal Officer and Corporate Secretary since January 2017 and as a member of the board of directors of OptiNose AS since June 2018. Prior to joining Optinose, Mr. Marino served as Senior Vice President, General Counsel and Corporate Secretary of Fibrocell Science, Inc., a publicly-traded cell and gene therapy company, from 2015 to 2017, and as Senior Vice President, General Counsel and Corporate Secretary of NuPathe Inc., a publicly-traded specialty pharmaceutical company from 2010 until the sale of NuPathe to Teva Pharmaceutical Industries Ltd. in 2014. From 2001 to 2010, Mr. Marino was an attorney at the law firms of Morgan, Lewis & Bockius LLP and WilmerHale LLP where his practice focused on mergers and acquisitions, financing transactions, collaborations, corporate governance, securities and other general corporate matters. Mr. Marino earned a B.S. in Accountancy from Villanova University and a J.D. from Boston College Law School.
- David Pernock
David Pernock自2009年9月担任董事会主席，同时自2010年2月担任首席执行官。从1993年12月到2009年11月，Pernock先生在葛兰素史克公司担任各种职务，最终担任制药、疫苗生物制剂、肿瘤、急性病护理以及艾滋病毒部门的高级副总裁。从2009年5月到2011年2月，Pernock先生担任Martek生物科学公司的董事。Pernock先生从亚利桑那州立大学获得企业管理学士学位。Pernock先生在董事会和管理委员会之间进行沟通，并监管管理委员会以实现董事会到的战略目标。
David Pernock has served as our President and Chief Commercial Officer since January 2017. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017 Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009 Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines biologics, oncology, acute care, and HIV divisions. From May 2009 until February 2011 Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University.- David Pernock自2009年9月担任董事会主席，同时自2010年2月担任首席执行官。从1993年12月到2009年11月，Pernock先生在葛兰素史克公司担任各种职务，最终担任制药、疫苗生物制剂、肿瘤、急性病护理以及艾滋病毒部门的高级副总裁。从2009年5月到2011年2月，Pernock先生担任Martek生物科学公司的董事。Pernock先生从亚利桑那州立大学获得企业管理学士学位。Pernock先生在董事会和管理委员会之间进行沟通，并监管管理委员会以实现董事会到的战略目标。
- David Pernock has served as our President and Chief Commercial Officer since January 2017. Previously, Mr. Pernock served as a member of our Board from April 2015 until January 2017. Before becoming our President and Chief Commercial Officer in January 2017 Mr. Pernock served as chairman of the board of directors since September 2009 and as chief executive officer since February 2010 of Fibrocell Science, Inc., a publicly-traded autologous cell and gene therapy company. From December 1993 until November 2009 Mr. Pernock held various positions at GlaxoSmithKline, eventually serving as senior vice president of pharmaceuticals, vaccines biologics, oncology, acute care, and HIV divisions. From May 2009 until February 2011 Mr. Pernock served as a director of Martek Biosciences Corporation. Mr. Pernock holds a B.S. in business administration from Arizona State University.